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INTRODUCTION
Photodynamic therapy (PDT) was approved as
a treatment for age-related macular degeneration
(AMD) in Japan since May, 2004. The number of
institutions dealing with PDT and cases actually
done have been increasing year by year. PDT has
been regarded as the treatment of choice for AMD
now. Recently many studies on PDT were reported
and some studies mentioned that PDT has shown
more effective than the results of The Japanese
AMD Trial, an open- label, multicenter, prospective,
and noncontrolled study (1). On the other hand, the
number of reports on the complications of PDT has
been increasing (2 - 5). Massive subretinal hemor-
rhage, one of the side effects after PDT, might lead
to grave visual disturbance. However the cause or
mechanism of subretinal hemorrhage after PDT is
still unclear. We report four cases with massive
subretinal hemorrhage after PDT.
PATIENTS AND METHODS
This study consisted of retrospective consecutive
series of patients who were treated with PDT for
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AMD at our university hospital from October 2004
to September 2006. All patients gave their informed
consent to be treated with PDT. A total of 4 cases
with massive subretinal hemorrhage out of 149
cases undergone PDT were investigated carefully.
All patients underwent pretreatment ophthalmologi-
cal examinations including visual acuity (VA), fluo-
rescein angiography (FA), indocyanin green angi-
ography (IA), and an optical coherence tomograph
(OCT, Stratus OCT3000 ; Carl Zeiss, Dublin, CA,
USA). We also studied spot size, period to the on-
set of hemorrhage, visual acuity before and after
PDT. We defined as massive subretinal hemorrhage
if the spread is more than the area of vasucular ar-
cade of the retina.
RESULTS
Among 149 cases treated with PDT, 103 cases
were AMD and 46 cases were polypoidal choroidal
vasculopathy (PCV). The four cases consisted of
one with AMD and 3 with PCV. The incidence of
massive subretinal hemorrhage is 3 (6.5%) of 46
cases with PCV and one (0.9%) of 103 cases with
AMD. Therefore, the incidence is much higher in
the patients with PCV than the patients with AMD.
The average spot size of PDT was 5525 μm. Two
out of four patients underwent the second PDT
about 3 months after the initial PDT. The periods
to the onset of hemorrhage were 22, 27, 137, and
208 days respectively. The latter 2 cases underwent
PDT twice, and the period was calculated from the
initial PDT. Two patients underwent vitrectomy. The
average VA before PDT was 0.20, and the final was
0.02 after PDT. The profiles of these four cases were
shown in Table 1. The following is a typical case.
Case 1
A 78 -year - old woman was diagnosed as macu-
lar degeneration in her right eye four months be-
fore and followed up by a nearby doctor. Her visual
acuity deteriorated gradually, then she was referred
to our hospital on September 21, 2005. On exami-
nation, her visual acuities were 0.4 in the right and
0.7 in the left eye. Intraocular pressure was normal
in both eyes and no abnormal findings were ob-
served in the anterior segment and the ocular me-
dia. A subretinal hemorrhage, fibrin, hard exudate,
and reddish -orange nodules were recognized in the
right macula (Fig. 1). Fluorescein angiography (FA)
showed leakage and hyperfluorescence at the lesion,
Table 1 The profiles of four cases with massive subretinal hemorrhage after PDT
Case AgeSex
Type of
disease
Spot
size
(μm)
Period to the
onset of
hemorrhage
Visual acuity1
before PDT
Visual acuity1
after PDT
Vitrec-
tomy
Previous
disease
1 78 Female PCV 4800 22days 0.4 0.02
2 88 Male PCV 6400 27days 0.2p 0.01 Done Hyper - tensionAnemia
3 80 Male PCV 5600 125days(208days)2 0.4
m.m/
30cm
4 76 Male AMD 5300 72days(137days)2 0.05 0.08 Done
Hyper - tension
Atrial fibrillation
1)visual acuity is corrected eyesight
2)case3 and 4 underwent PDT twice, and the days after initial the PDT are shown in parentheses
Fig. 1 Clinical photograph before PDT showed a subretinal hemorrhage, fibrin, hard exudate, and reddish -orange nodules were
recognized in the right macula
S. Matsushita, et al. Massive subretinal hemorrhage after PDT232
showing classic choroidal neovascularization (CNV)
(Fig. 2). Indocyanine green angiography (IA)
showed multiple polypoidal choroidal vascular le-
sions (Fig. 3). She was diagnosed as PCV from
these findings. PDT was performed with a 4800
μm spot size, as guided by the abnormalities shown
in the FA on October, 28, 2005. No complications
were recognized during the treatment. The patient
complained of a rapid decrease in her right vision
on 22 days after PDT. We fond the massive subreti-
nal hemorrhage which spread more than the area
of vasucular arcade of the retina in her right eye
on November 30, 2005 (Fig. 4). Her right visual acu-
ity decreased to 0.04. She was followed up and
treated with oral use of carbazochrome sodium sul-
fonate. Despite the absorption of the hemorrhage,
fibrin deposition and organization of the hemorrhage
were recognized. The final visual acuity became
0.02.
Fig. 3 Indocyanine green angiography showed multiple polypoidal choroidal vascular lesions.
Fig. 2 Fluorescein angiography before PDT showed leakage and hyperfluorescence at the lesion, showing classic choroidal ne-
ovascularization.
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DISCUSSION
Although our number is limited, three of 4 cases
were PCV. The incidence of massive subretinal
hemorrhage is 6.5% in the patients with PCV and
almost same as the previous report (11). The inci-
dence is much higher in the patients with PCV
than the patients with AMD. Therefore, our study
alarms that PDT for PCV seems to cause massive
subretinal hemorrhage. Spot size of 4 cases was
relatively large. Two out of four patients had mas-
sive subretinal hemorrhage after the second PDT,
so care must be taken even if subretinal hemor-
rhage dose not appear after the initial PDT. But it
is not clear whether PDT itself causes massive
subretinal hemorrhage or not, because the periods
to the onset of hemorrhage of thses 2 cases were
long. Among Japanese the proportion of PCV
among exudative AMD is large (6), and PDT for
PCV has shown to be more effective than that for
other types of AMD (7-10). This leads that we
have more chance of PDT for PCV and the num-
ber of cases with subretinal hemorrhage after PDT
will increase. PDT itself leads to inflammation at
the exposure field and ischemia by angiopathic
mechanism. The inflammation or ischemia produces
vascular endothelial growth factor(VEGF) in the
retina, and then angiogenesis or vascular perme-
ability occurs. That may trigger subretinal hemor-
rhage. Larger spot size is likely to induce wide-
spread inflammation and ischemia, and trigger
subretinal hemorrhage. Recently, IA is more popu-
lar than FA in guiding a suitable laser spot size.
This enables to treat by minimal greatest linear di-
mension (GLD) and to minimize inflammation and
ischemia by PDT. But it is possible that we fail to
cover lesions hiding under hemorrhage when PDT
is delivered only as guided by the abnormalities
shown by IA. Especially it is necessary to cover le-
sions like abnormal network of choroidal neovas-
cularization in PDT for PCV, in order to prevent a
recurrence or hemorrhage after PDT. From now
on, we need comprehensively check lesions and
conditions from findings not only of FA and IA, but
also of OCT. Then custom-made treatment for each
case can be done. We also should consider PDT
combined with juxafoveal injection of triamcinolone
acetonide or intravitreous injection of anti -VEGF
antibodies.
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